First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function

Midori Hasegawa, Nobuya Kitaguchi, Hajime Takechi, Kazunori Kawaguchi, Kengo Ito, Takashi Kato, Masao Kato, Norio Nii, Sachie Yamada, Atsushi Ohashi, Shigehisa Koide, Hiroki Hayashi, Kazuo Takahashi, Daijo Inaguma, Yukio Yuzawa, Naotake Tsuboi

研究成果: Article査読

抄録

Introduction: Amyloid β (Aβ) is a brain protein that causes Alzheimer's disease (AD). This study aimed to verify whether hemadsorption using a hexadecyl-alkylated cellulose bead (HexDC) column removes blood Aβ and brain Aβ accumulation in mild cognitive impairment/mild AD cases with normal kidney function. Methods: Two patients with positive Aβ on brain imaging underwent HexDC hemadsorption weekly for 6 months. Results: The Aβ removal efficiency of HexDC was 87–99%. Aβ1−40/Aβ1−42 influx into the blood in one session was 596/56 and 489/48 ng for Case A and Case B, respectively. Although brain Aβ accumulation did not clearly change after 6 months of hemadsorption, cognitive functions measured by the two tests were maintained or slightly improved. Conclusion: Blood Aβ removal was performed in two early AD patients with normal kidney function without adverse events, and it slightly improved or maintained cognitive function.

本文言語English
ページ(範囲)529-536
ページ数8
ジャーナルTherapeutic Apheresis and Dialysis
26
3
DOI
出版ステータスPublished - 06-2022

All Science Journal Classification (ASJC) codes

  • 血液学
  • 腎臓病学

フィンガープリント

「First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル